GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-12-2326-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.74 million
Profitability
Miscellaneous
Employees791
Next Earnings Date11/26/2019 (Estimated)
OptionableOptionable
GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions
What is GW Pharmaceuticals PLC-'s stock symbol?
GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."
How were GW Pharmaceuticals PLC-'s earnings last quarter?
GW Pharmaceuticals PLC- (NASDAQ:GWPH) posted its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.74) by $0.96. The biopharmaceutical company had revenue of $72.04 million for the quarter, compared to analyst estimates of $37.28 million. GW Pharmaceuticals PLC- had a negative net margin of 101.45% and a negative return on equity of 38.09%. GW Pharmaceuticals PLC-'s revenue was up 2096.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.25) EPS. View GW Pharmaceuticals PLC-'s Earnings History.
When is GW Pharmaceuticals PLC-'s next earnings date?
What price target have analysts set for GWPH?
11 equities research analysts have issued 12 month target prices for GW Pharmaceuticals PLC-'s stock. Their predictions range from $185.00 to $239.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $215.00 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.
What is the consensus analysts' recommendation for GW Pharmaceuticals PLC-?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.
What are Wall Street analysts saying about GW Pharmaceuticals PLC- stock?
Here are some recent quotes from research analysts about GW Pharmaceuticals PLC- stock:
- 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (8/12/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating on GW Pharmaceuticals and raising our 12-month price target to $196/ADS from $193/ ADS following the announced sale of Voucher (PRV). As a reminder, GW Pharmaceuticals was awarded the PRV following the EPIDIOLEX approval last year. The recipient of the PRV was not announced in the press release." (3/18/2019)
Has GW Pharmaceuticals PLC- been receiving favorable news coverage?
Media headlines about GWPH stock have trended positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GW Pharmaceuticals PLC- earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for GW Pharmaceuticals PLC-.
Who are some of GW Pharmaceuticals PLC-'s key competitors?
Some companies that are related to GW Pharmaceuticals PLC- include GRIFOLS S A/S (GRFS), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Array Biopharma (ARRY), Ionis Pharmaceuticals (IONS), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), SAGE Therapeutics (SAGE), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA) and Bausch Health Companies (BHC).
What other stocks do shareholders of GW Pharmaceuticals PLC- own?
Who are GW Pharmaceuticals PLC-'s key executives?
GW Pharmaceuticals PLC-'s management team includes the folowing people:
- Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
- Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
- Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
- Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
- Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)
Who are GW Pharmaceuticals PLC-'s major shareholders?
GW Pharmaceuticals PLC-'s stock is owned by a number of of institutional and retail investors. Top institutional investors include Prudential PLC (3.49%), Victory Capital Management Inc. (2.48%), Point72 Asset Management L.P. (2.22%), Rock Springs Capital Management LP (2.01%), ETF Managers Group LLC (1.91%) and Morgan Stanley (1.71%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Institutional Ownership Trends for GW Pharmaceuticals PLC-.
Which institutional investors are selling GW Pharmaceuticals PLC- stock?
GWPH stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Janus Henderson Group PLC, Janus Henderson Group PLC, Pictet Asset Management Ltd., Pictet Asset Management Ltd., BlackRock Inc., Bank of America Corp DE and Prudential PLC. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Insider Buying and Selling for GW Pharmaceuticals PLC-.
Which institutional investors are buying GW Pharmaceuticals PLC- stock?
GWPH stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., ETF Managers Group LLC, Victory Capital Management Inc., Nuveen Asset Management LLC, Marshall Wace North America L.P., Sio Capital Management LLC, Invesco Ltd. and Morgan Stanley. View Insider Buying and Selling for GW Pharmaceuticals PLC-.
How do I buy shares of GW Pharmaceuticals PLC-?
Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GW Pharmaceuticals PLC-'s stock price today?
One share of GWPH stock can currently be purchased for approximately $145.46.
How big of a company is GW Pharmaceuticals PLC-?
GW Pharmaceuticals PLC- has a market capitalization of $4.39 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-295,160,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.View Additional Information About GW Pharmaceuticals PLC-.
What is GW Pharmaceuticals PLC-'s official website?
How can I contact GW Pharmaceuticals PLC-?
GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]
MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
